A review of expression profiling of circulating microRNAs in men with prostate cancer

BJU International

Volumn 111, Issue 1, 2013, Pages 17-21

  Kelly, Brian D ^a,b   Miller, Nicola ^a   Healy, Nuala A ^a   Walsh, Kilian ^b   Kerin, Michael J ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

circulation; miRNA; prostate cancer

Indexed keywords

MICRORNA; MICRORNA 141; MICRORNA 155; MICRORNA 195; MICRORNA 21; MICRORNA 221; MICRORNA 26A; MICRORNA 375; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; BLOOD SAMPLING; CANCER GRADING; CANCER GROWTH; CELL TYPE; DIAGNOSTIC ACCURACY; DISEASE MARKER; EXOSOME; GENE EXPRESSION PROFILING; GENE FUNCTION; HUMAN; MICROVASCULATURE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA EXTRACTION; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; UPREGULATION;

EID: 84871615149     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11244.x     Document Type: Review

References (38)

1. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM,. MicroRNA expression and function in cancer. Trends Mol Med 2006; 12: 580-587
2. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-7070
3. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-15529
4. Michael MZ, O'Connor SM, van, Holst Pellekaan NG, Young GP, James RJ,. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003; 1: 882-891
5. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838
6. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A,. Identification of mammalian microRNA host genes and transcription units. Genome Res 2004; 14: 1902-1910
7. Lewis BP, Burge CB, Bartel DP,. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20
8. Vrba L, Jensen TJ, Garbe JC, et al. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS ONE 2010; 5: e8697
9. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004; 23: 4051-4060
10. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ,. Processing of primary microRNAs by the Microprocessor complex. Nature 2004; 432: 231-235
11. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U,. Nuclear export of microRNA precursors. Science 2004; 303: 95-98
12. Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN,. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev 2004; 18: 3016-3027
13. Winter J, Jung S, Keller S, Gregory RI, Diederichs S,. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11: 228-234
14. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518
15. Esquela-Kerscher A, Slack FJ,. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269
16. Xi Y, Nakajima G, Gavin E, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007; 13: 1668-1674
17. Tanaka M, Oikawa K, Takanashi M, et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS ONE 2009; 4: e5532
18. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009; 58: 1375-1381
19. Taylor DD, Gercel-Taylor C,. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110: 13-21
20. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006
21. Skog J, Wurdinger T, van, Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008; 10: 1470-1476
22. Hunter MP, Ismail N, Zhang X, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 2008; 3: e3694
23. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108: 5003-5008
24. Brase JC, Johannes M, Schlomm T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011; 128: 608-616
25. Mahn R, Heukamp LC, Rogenhofer S, von, Ruecker A, Muller SC, Ellinger J,. Circulating microRNAs (miRNA) in Serum of Patients With Prostate Cancer. Urology 2011; 77: 1265 e9-e16
26. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B,. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS ONE 2009; 4: e6229
27. Zhang HL, Yang LF, Zhu Y, et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011; 71: 326-331
28. Yaman Agaoglu F, Kovancilar M, Dizdar Y, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 2011; 32: 583-588
29. Zheng C, Yinghao S, Li J,. MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2. Med Oncol 2012; 29: 815-822
30. Moltzahn F, Olshen AB, Baehner L, et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 2011; 71: 550-560
31. Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ,. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 2010; 15: 673-682
32. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ,. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010; 251: 499-505
33. Pritchard CC, Kroh E, Wood B, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 2012; 5: 492-497
34. Heneghan HM, Miller N, Kerin MJ,. Circulating miRNA signatures: promising prognostic tools for cancer. J Clin Oncol 2010; 28: e573-576
35. Ge Y, Xiao L, Chen X, Peng Y, Sun L, Liu F,. MicroRNAs in peritoneal dialysis effluent are promising biomarkers for peritoneal fibrosis in peritoneal dialysis patients. Med Hypotheses 2012; 78: 155-156
36. Liu CJ, Lin SC, Yang CC, Cheng HW, Chang KW,. Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head Neck 2012; 34: 219-224
37. Yamada Y, Enokida H, Kojima S, et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci 2011; 102: 522-529
38. Selth LA, Townley S, Gillis JL, et al. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer 2011; DOI: 10.1002/ijc.26405